Ripple Therapeutics partnership for development and testing of drug delivery system

位于安大略省多伦多的一家分拆公司涟漪治疗公司， 地塞米松皮质类固醇眼睛药物递送系统不涉及使用聚合物载体。 赋形剂，提供对药物释放的上级控制。正在进行的关于这一系统的工作涉及 开发以不同浓度和不同浓度释放地塞米松的原型材料 rates.麦克马斯特大学的Sheardown实验室与涟漪合作将开发新的地塞米松 其包含显示出可针对应用定制的释放速率的体系。这将是重要的，因为 该小组对治疗相关浓度进行了了解。这些系统将被 其特征在于药物释放以及生物相容性和药物在眼中的分布。最终这 系统将通过涟漪管道向前移动，用于治疗各种眼部疾病， 包括用目前的剂型难以治疗的葡萄膜炎。

Ripple Therapeutics, a spin out company located in Toronto ON, has a novel method of delivering dexamethasone, a corticosteroid, the eye. The drug delivery system does not involve the use of polymeric excipients, providing superior control over the release of drug. Ongoing work on this system involves the development of prototype materials that release dexamethasone at different concentrations and at different rates. The Sheardown lab at McMaster University in partnership with Ripple will develop new dexamethasone containing systems which show release rates that can be tailored for the application. This will be important as the team develops an understanding of therapeutically relevant concentrations. The systems will be characterized for drug release as well as biocompatibility and drug distribution in the eye. Ultimately, this system will be moved forward through the Ripple pipeline for the treatment of various ocular conditions, including uveitis, which is difficult to treat with current dosage forms.